StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
4
Publishing Date
2024 - 04 - 18
3
2024 - 04 - 17
2
2024 - 04 - 15
2
2024 - 02 - 20
2
2024 - 01 - 08
2
2023 - 12 - 07
2
2023 - 12 - 06
4
2023 - 10 - 11
4
2023 - 10 - 05
3
2023 - 10 - 02
2
2023 - 09 - 26
2
2023 - 07 - 19
2
2023 - 06 - 02
2
2023 - 05 - 31
2
2023 - 05 - 25
2
2023 - 03 - 21
2
2023 - 02 - 23
2
2023 - 02 - 13
3
2023 - 01 - 03
2
2022 - 10 - 26
4
2022 - 10 - 13
2
2022 - 09 - 15
2
2022 - 06 - 28
2
2022 - 06 - 24
2
2022 - 05 - 31
2
2022 - 04 - 04
2
2022 - 03 - 28
2
2022 - 03 - 11
2
2021 - 12 - 02
2
2021 - 11 - 09
2
2021 - 10 - 14
2
2021 - 10 - 13
4
2021 - 10 - 07
2
2021 - 09 - 30
2
2021 - 09 - 29
4
2021 - 08 - 02
2
2021 - 06 - 18
2
2021 - 05 - 25
3
2021 - 04 - 16
2
2021 - 04 - 15
3
2021 - 03 - 19
3
2021 - 02 - 25
1
2021 - 02 - 23
1
2021 - 02 - 19
1
2021 - 02 - 18
1
2021 - 02 - 02
1
2021 - 01 - 19
1
2021 - 01 - 18
1
2021 - 01 - 14
1
2021 - 01 - 11
1
2020 - 12 - 21
1
2020 - 12 - 10
1
2020 - 11 - 09
1
2020 - 10 - 19
1
2020 - 10 - 14
1
2020 - 10 - 08
1
2020 - 09 - 08
1
2020 - 06 - 29
1
2020 - 05 - 27
1
2020 - 05 - 12
1
Sector
Health technology
4
Tags
Acquisition
3
Agreement
11
America
5
Application
4
Approval
3
Battery
3
Biotech-bay
3
Biotech-beach
5
Cancer
8
Care
3
Ceo
5
Clinical-trials-phase-ii
3
Conference
45
Contract
4
Corporation
12
Distribution
5
Earnings
6
Energy
10
Europe
4
Financial
81
Genetown
4
Global
16
Group
15
Growth
14
Health
11
Innovation
4
International
4
Management
8
Market
28
Meeting
8
Molecular
5
N/a
459
Nasdaq
4
Offering
10
Pharma
5
Pharmaceutical
5
Pharmaceuticals
9
Phase 1
8
Phase 2b
5
Positive
4
Preclinical
5
Presentation
6
Program
7
Report
38
Research
6
Results
126
Sales
4
Sciences
4
Sclerosis
4
Services
6
Solutions
5
Study
16
Symposium
6
System
8
Technology
8
Therapeutics
29
Treatment
9
Trial
13
Update
18
Year
8
Entities
Atara biotherapeutics, inc.
1
Bristol-myers squibb company
1
Tg therapeutics, inc.
1
Tiziana life sciences plc
1
Symbols
ATRA
1
BMY
1
TGTX
1
TLSA
1
Exchanges
Nasdaq
3
Nyse
1
Crawled Date
2022 - 10 - 26
4
Crawled Time
07:00
1
08:00
1
11:00
1
12:00
1
Source
www.biospace.com
2
www.globenewswire.com
2
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
publishing date :
2022 - 10 - 26
tags :
Sclerosis
save search
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis
Published:
2022-10-26
(Crawled : 12:00)
- globenewswire.com
TGTX
|
$14.25
1.06%
1.05%
3.2M
|
Health Technology
|
162.08%
|
O:
-0.93%
H:
11.07%
C:
3.75%
treatment
trials
research
therapeutics
presentation
sclerosis
multiple sclerosis
Tiziana Life Sciences Starts Enrollment of the First Patient Cohort in its Intermediate Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients
Published:
2022-10-26
(Crawled : 11:00)
- globenewswire.com
TLSA
|
News
|
$0.7501
-0.46%
-0.47%
2.5M
|
Health Technology
|
2.24%
|
O:
0.19%
H:
0.0%
C:
-2.05%
sciences
life
program
foralumab
sclerosis
Atara Biotherapeutics Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022
Published:
2022-10-26
(Crawled : 08:00)
- biospace.com/
ATRA
|
$0.7199
3.23%
3.13%
830K
|
Health Technology
|
-85.07%
|
O:
-0.21%
H:
5.77%
C:
1.07%
ata188
extension
sclerosis
study
phase 1
New Zeposia (ozanimod) Data Highlight COVID-19 Outcomes and Preservation of Long-Term Cognitive Function from Separate Analyses in Patients with Relapsing Forms of Multiple Sclerosis
Published:
2022-10-26
(Crawled : 07:00)
- biospace.com/
BMY
|
$48.99
-0.31%
0.0%
9.1M
|
Health Technology
|
-32.47%
|
O:
0.44%
H:
2.9%
C:
1.86%
covid-19
sclerosis
Gainers vs Losers
79%
21%
Top 10 Gainers
MTTR
|
News
M
|
$4.6
164.37%
62.17%
28M
|
AGBA
|
$2.94
135.2%
57.48%
66M
|
Finance
EDBL
|
News
|
$6.46
71.81%
41.8%
2M
|
MTC
|
$2.25
44.23%
30.67%
6M
|
Technology Services
OPRT
|
News
|
$3.175
41.11%
29.13%
12M
|
Finance
SHIM
|
$3.05
35.56%
26.23%
870K
|
HKIT
|
$1.345
31.86%
24.16%
390K
|
Technology Services
ABVC
|
$1.36
30.77%
23.53%
7.4M
|
Wholesale Trade
OST
|
$0.512
28.0%
21.88%
290K
|
POET
|
$1.59
27.2%
21.38%
4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.